Proteomics-based Anticancer Drug Discovery and Development

被引:10
|
作者
Jain, K. K. [1 ]
机构
[1] Jain PharmaBiotech, CH-4057 Basel, Switzerland
关键词
Cancer; proteomics; drug discovery; drug targets; target validation; anticancer drugs;
D O I
10.1177/153303460200100403
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Proteins are important targets for drug discovery and this applied to cancer as well because there is a defect in the protein machinery of the cell in malignancy. Proteomic technologies are now being integrated with genomic approaches for cancer drug discovery and target validation. Among the large number of proteomic technologies available for this purpose, the most important ones are 3-D protein structure determination, protein microarrays, laser capture microdissection and study of protein-protein and protein-drug interactions. Cancer biomarkers and several cell pathways are important drug targets. Several companies are involved in using proteomic technologies for drug discovery. Finally, proteomic approaches will play an important role in the discovery and development of personalized medicines.
引用
收藏
页码:231 / 236
页数:6
相关论文
共 50 条
  • [21] Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery
    Hu, Shen
    Yen, Yun
    Ann, David
    Wong, David T.
    DRUG DISCOVERY TODAY, 2007, 12 (21-22) : 911 - 916
  • [22] Quantitative and targeted proteomics-based identification and validation of drug efficacy biomarkers
    Masuda, Takeshi
    Mori, Ayano
    Ito, Shingo
    Ohtsuki, Sumio
    DRUG METABOLISM AND PHARMACOKINETICS, 2021, 36
  • [23] Development of a rapid and comprehensive proteomics-based arboviruses detection system
    Okamoto, Kenta
    Endo, Yushirou
    Inoue, Shingo
    Nabeshima, Takeshi
    Phan Thi Nga
    Guillermo, Posadas H.
    Yu, Fuxun
    Do Phuong Loan
    Bui Minh Trang
    Natividad, Filipinas F.
    Hasebe, Futoshi
    Morita, Kouichi
    JOURNAL OF VIROLOGICAL METHODS, 2010, 167 (01) : 31 - 36
  • [24] Discovery and development of novel anticancer drug capecitabine
    Ishitsuka, H
    Shimma, N
    Horii, I
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 1999, 119 (12): : 881 - 897
  • [25] Anticancer drug discovery and development throughout the world
    Schwartsmann, G
    Ratain, MJ
    Cragg, GM
    Wong, JE
    Saijo, N
    Parkinson, DR
    Fujiwara, Y
    Pazdur, R
    Newman, DJ
    Dagher, R
    Di Leone, L
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) : 47S - 59S
  • [26] Proteomics-based diagnostic peptide discovery for severe fever with thrombocytopenia syndrome virus in patients
    Lee, Sang-Yeop
    Lee, Hayoung
    Yun, Sung Ho
    Park, Edmond Changkyun
    Seo, Giwan
    Kim, Hye-Yeon
    Jun, Sangmi
    Kim, Nam Hoon
    Tark, Dongseob
    Lee, Ju Yeon
    Lee, Chang-Seop
    Kim, Seung Il
    CLINICAL PROTEOMICS, 2022, 19 (01)
  • [28] Proteomics-based Precision Medicine Strategies
    Haura, Eric B.
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2024, 65 : 14 - 14
  • [29] Serum biomarkers in patients with drug-resistant epilepsy: a proteomics-based analysis
    Ma, Mian
    Cheng, Ying
    Hou, Xiaoxia
    Li, Zhisen
    Wang, Meixia
    Ma, Bodun
    Cheng, Qingzhang
    Ding, Zhiliang
    Feng, Hongxuan
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [30] Anti-migratory activity of marine alkaloid monanchocidin A - proteomics-based discovery and confirmation
    Dyshlovoy, Sergey A.
    Venz, Simone
    Hauschild, Jessica
    Tabakmakher, Ksenya M.
    Otte, Katharina
    Madanchi, Ramin
    Walther, Reinhard
    Guzii, Alla G.
    Makarieva, Tatyana N.
    Shubina, Larisa K.
    Fedorov, Sergey N.
    Stonik, Valentin A.
    Bokemeyer, Carsten
    Balabanov, Stefan
    Honecker, Friedemann
    Amsberg, Gunhild V.
    PROTEOMICS, 2016, 16 (10) : 1590 - 1603